EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19

Aisling R Caffrey iD, Haley J Appaneal iD, Vrishali V Lopes, Thomas Lavoie, Laura Puzniak, Evan J Zasowski, Luis Jodar, Iqra Arham, Kerry L LaPlante iD, John M McLaughlin

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.03209-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Aisling R Caffrey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Ritonavir, Anti-Bacterial Agents, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) has complicated the management of acute respiratory infections and impacted antibiotic use. We assessed the relationship between nirmatrelvir/ritonavir (NMV/r) receipt and outpatient antibiotic prescribing among patients with COVID-19 in a large national health system. We conducted a retrospective cohort study among outpatients enrolled in the Veterans Affairs Healthcare System who had a positive severe acute respiratory syndrome coronavirus 2 test or COVID-19 diagnosis and were eligible for NMV/r treatment between 1 April 2022 and 31 March 2024. NMV/r-treated patients were compared with those who did not receive NMV/r and were considered unexposed until NMV/r was dispensed. We assessed the relationship between NMV/r receipt and being prescribed an outpatient antibiotic in the 30 days after a COVID-19 diagnosis using adjusted Cox proportional hazards regression. We included 302,600 NMV/r-eligible outpatients with COVID-19, of whom 67,649 received NMV/r and 234,951 did not receive NMV/r. NMV/r-treated patients were less likely to receive outpatient antibiotics compared to those who did not receive NMV/r (7.2% [4,901/67,649] vs 9.2% [21,533/234,951], respectively; adjusted hazard ratio [HR] 0.65, 95% CI: 0.63‒0.68). After excluding patients who received an antibiotic prescription upon COVID-19 diagnosis (i.e., likely empiric therapy), this relationship was attenuated (HR: 0.91, 95% CI: 0.87‒0.95). NMV/r-eligible patients with COVID-19 who received NMV/r were 35% less likely to be prescribed outpatient antibiotics compared to patients who did not receive NMV/r, possibly driven by a diminished perceived need for empiric antibiotic therapy. Treatment with NMV/r may reduce unnecessary outpatient antibiotic use. Antibiotics should be reserved for patients with a high suspicion of bacterial co-infection. IMPORTANCE Antimicrobial resistance, driven by the overuse of antibiotics, is a major global health threat. The coronavirus disease 2019 (COVID-19) pandemic has complicated this issue, with antibiotics often prescribed to patients with COVID-19 despite being ineffective against viruses. These practices, typically aimed at preventing or empirically treating rare bacterial co-infections, have raised concerns about accelerating resistance. The antiviral nirmatrelvir/ritonavir (NMV/r), widely used in high-risk patients with COVID-19 to prevent severe illness, offers an opportunity to reassess antibiotic use in patients with respiratory infections. Our study of over 300,000 patients in a national healthcare system found that those treated with NMV/r for COVID-19 were 35% less likely to receive antibiotics than those who did not receive the antiviral. Lower antibiotic use among patients treated with NMV/r may reflect a reduction in unnecessary outpatient antibiotic use. These findings highlight the potential role of antivirals in supporting antibiotic stewardship and addressing a critical public health challenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirAnti-Bacterial AgentsCOVID-19 Drug TreatmentCOVID-19Antiviral AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedOutpatientsSARS-CoV-2Drug Prescriptions

Stichwörter der Autor:innen

COVID-19antibioticsco-infectionnirmatrelvir/ritonavirstewardship

Substanzen

RitonavirAnti-Bacterial AgentsAntiviral Agents

Autor:innen und Institutionen

  • Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
  • Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
  • College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
  • School of Public Health, Brown University, Providence, Rhode Island, USA.
  • Pfizer Inc., New York, New York, USA.

ORCID-Profile: Aisling R Caffrey, Haley J Appaneal, Kerry L LaPlante

Förderung

  • Pfizer, Inc

Zitieren

APA

Caffrey, A. R., Appaneal, H. J., Lopes, V. V., Lavoie, T., Puzniak, L., Zasowski, E. J., Jodar, L., Arham, I., LaPlante, K. L., & McLaughlin, J. M. (2025). Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03209-24

Vancouver

Caffrey AR, Appaneal HJ, Lopes VV, Lavoie T, Puzniak L, Zasowski EJ, et al. Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19. Microbiology Spectrum. 2025. doi:10.1128/spectrum.03209-24

BibTeX
@article{Caffrey2025,
  author = {Caffrey, Aisling R and Appaneal, Haley J and Lopes, Vrishali V and Lavoie, Thomas and Puzniak, Laura and Zasowski, Evan J and Jodar, Luis and Arham, Iqra and LaPlante, Kerry L and McLaughlin, John M},
  title = {Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.03209-24}
}
Kostenlos starten →